TP53 and non-small cell lung carcinoma: Metformin was shown to inhibit the DNA damage repair pathway in pancreatic cancer [25], p53-deficient colorectal cancer [26], and non-small cell lung cancer (NSCLC) cells [27] by downregulating RAD51, indicating the anticancer effects of metformin.